Screener
IDNA vs PJP
iShares Genomics Immunology and Healthcare ETF vs Invesco Pharmaceuticals ETF
Key differences
- IDNA costs 0.10% less per year.
- Over the last 3 years, PJP has delivered higher annualized returns.
- PJP has a longer track record, which may reduce uncertainty around long-term behavior.
Side-by-side comparison
| IDNA | PJP | |
|---|---|---|
| Annual cost (TER) | 0.47% | 0.57% |
| Fund size (AUM) | $160M | $334M |
| Since | 2019 | 2005 |
| Dividend yield | 1.05% | 1.01% |
| Asset class | equity | equity |
| Region | — | north america |
| Strategy | index tracking | index tracking |
| CAGR 1Y | +49.2% | +38.9% |
| CAGR 3Y | +8.0% | +14.0% |
| CAGR 5Y | -7.5% | +7.4% |
| Sharpe 3Y | 0.29 | 0.69 |
| Volatility 1Y | 24.43% | 16.19% |
| Max drawdown | -68.26% | -33.95% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to IDNA and PJP
Explore further